Back

From 24‑hour blood pressure to cardiorenal outcomes and future directions

30 August 2026 (13:06 - 13:17)
Organised by: Logo
Congress Presentation Part of: 24-hour blood pressure burden: aldosterone, cardiorenal risk, and the next generation of blood pressure control Renin-Angiotensin System Open Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Pam Taub

University of California San Diego, La Jolla (United States of America)

5 More presentations in this session

Presentation thumbnail
Welcome, introduction, program framing, review of objectives
Professor G. Parati (Milan, IT)
Video
Presentation thumbnail
Aldosterone and the 24-hour blood pressure burden
Professor R. Cifkova (Prague, CZ)
Video
Presentation thumbnail
Ambulatory blood pressure monitoring‑detected 24‑hour blood pressure phenotypes in resistant hypertension
Associate Professor G. Bilo (Milan, IT)
Video
Presentation thumbnail
Targeting aldosterone: what ambulatory blood pressure monitoring studies tell us about aldosterone synthase inhibition
Professor G. Parati (Milan, IT)
Video
Presentation thumbnail
24-hour blood pressure burden: aldosterone, cardiorenal risk, and the next generation of blood pressure control - Q&A
Video

Access the full session

Session thumbnail
24-hour blood pressure burden: aldosterone, cardiorenal risk, and the next generation of blood pressure control
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 13:06 CET
You may be interested in
thumbnail
Congress Presentation
Prognostic value of different circadian blood pressure patterns in ambulatory blood pressure monitoring
29 August 2026
thumbnail
Congress Presentation
Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
29 June 2021
thumbnail
Webinar
Highlights from the ESC Heart and Stroke Conference
14 October 2020
thumbnail
Congress Presentation
The significance of 24h blood pressure variability improvement regarding target organ damage indices three years after medical treatment initiation in essential hypertension
31 August 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources